Mol Imaging Biol 2011, 13:178–186.PubMedCrossRef 18. Kalin NH, Shelton SE, Fox AS, Rogers

J, Oakes TR, Davidson RJ: The serotonin transporter genotype is associated with intermediate brain phenotypes that depend on the context of eliciting stressor. Mol Psychiatry 2008, 13:1021–1027.PubMedCrossRef 19. Macheda ML, Rogers S, Best JD: Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol 2005, 202:654–662.PubMedCrossRef 20. Brown RS, Leung JY, Fisher SJ, Frey KA, Ethier SP, Wahl RL: Intratumoral distribution of tritiated-FDG in breast carcinoma: correlation between Glut-1 expression and FDG uptake. J Nucl Med 1996, 37:1042–1047.PubMed 21. Grabellus F, Nagarajah J, Nirogacestat clinical trial Bockisch A, EPZ-6438 mw Schmid KW, Sheu SY: Glucose transporter 1 expression, tumor proliferation, and iodine/glucose uptake in thyroid cancer with emphasis on poorly differentiated thyroid carcinoma. Clin Nucl Med 2012, 37:121–127.PubMedCrossRef 22. Hamada K, Tomita Y, Qiu Y, Zhang B, Ueda T, Myoui A, Higuchi I, Yoshikawa H, Aozasa K, Hatazawa

J: 18F-FDG-PET of musculoskeletal tumors: a correlation with the expression of glucose transporter 1 and hexokinase II. Ann Nucl Med 2008, 22:699–705.PubMedCrossRef 23. Westerterp M, Sloof GW, Hoekstra OS, Ten Kate FJ, Meijer GA, Reitsma JB, Boellaard learn more R, Van Lanschot JJ, Molthoff CF: 18FDG uptake in oesophageal adenocarcinoma: linking biology and outcome. J Cancer Res Clin Oncol 2008, 134:227–236.PubMedCrossRef 24. Hodgkinson AD, Millward BA, Demaine AG: Polymorphisms of the glucose transporter

(GLUT1) gene are associated with diabetic nephropathy. Kidney Int 2001, 59:985–989.PubMedCrossRef 25. Page T, Hodgkinson AD, Ollerenshaw M, Hammonds JC, Demaine AG: Glucose transporter polymorphisms are associated with clear-cell renal carcinoma. Cancer Genet Cytogenet 2005, 163:151–155.PubMedCrossRef 26. Amann T, Kirovski G, Bosserhoff AK, Hellerbrand C: Analysis of a promoter polymorphism of the GLUT1 gene in patients with hepatocellular carcinoma. Mol Membr Biol 2011, 28:182–186.PubMedCrossRef 27. Flavopiridol (Alvocidib) Semenza GL: HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med 2002, 8:S62-S67.PubMedCrossRef 28. Semenza GL: Hypoxia-inducible factor 1: master regulator of O2 homeostasis. Curr Opin Genet Dev 1998, 8:588–594.PubMedCrossRef 29. Talks KL, Turley H, Gatter KC, Maxwell PH, Pugh CW, Ratcliffe PJ, Harris AL: The expression and distribution of the hypoxia-inducible factors HIF1-alpha and HIF2-alpha in normal human tissues, cancers, and tumorassociated macrophages. Am J Pathol 2000, 57:411–421.CrossRef 30. Fu XS, Choi E, Bubley GJ, Balk SP: Identification of hypoxia-inducible factor-1alpha (HIF-1alpha) polymorphism as a mutation in prostate cancer that prevents normoxia-induced degradation. Prostate 2005, 63:215–221.PubMedCrossRef 31.